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Abstract
Background: There is a well established link between obesity and cancer. Emerging research is characterising this
relationship further and delineating the specific role of excess visceral adiposity, as opposed to simple obesity, in
promoting tumorigenesis. This review summarises the evidence from an epidemiological and pathophysiological
perspective.
Methods: Relevant medical literature was identified from searches of PubMed and references cited in appropriate
articles identified. Selection of articles was based on peer review, journal and relevance.
Results: Numerous epidemiological studies consistently identify increased risk of developing carcinoma in the
obese. Adipose tissue, particularly viscerally located fat, is metabolically active and exerts systemic endocrine effects.
Putative pathophysiological mechanisms linking obesity and carcinogenesis include the paracrine effects of adipose
tissue and systemic alterations associated with obesity. Systemic changes in the obese state include chronic
inflammation and alterations in adipokines and sex steroids. Insulin and the insulin-like growth factor axis influence
tumorigenesis and also have a complex relationship with adiposity. There is evidence to suggest that insulin and
the IGF axis play an important role in mediating obesity associated malignancy.
Conclusions: There is much evidence to support a role for obesity in cancer progression, however further research
is warranted to determine the specific effect of excess visceral adipose tissue on tumorigenesis. Investigation of the
potential mechanisms underpinning the association, including the role of insulin and the IGF axis, will improve
understanding of the obesity and cancer link and may uncover targets for intervention.
Methodology
Relevant medical literature was identified from searches
of PubMed and references cited in appropriate articles
identified. Search terms used included: obesity, over-
weight, cancer, adipose tissue, inflammation, insulin,
metabolic syndrome, adipokines and sex steroids. More
detailed search terms were used following identification
of relevant mechanisms and to identify epidemiological
studies. All meta-analyses addressing cancer incidence
with respect to body mass index were identified by
PubMed searches. Meta-analyses of cohort or nested
case control studies only were included. When available,
meta-analyses were preferentially cited as epidemiologi-
cal evidence. Selection of other articles was based on
peer review, journal and relevance. Where possible,
review articles from high impact factor peer-reviewed
journals were cited.
Introduction
The World Health Organisation defines obesity as an
abnormal or excessive fat accumulation in adipose tis-
sue, to the extent that health is impaired. The classifica-
tion of obesity for epidemiological purposes defines
overweight as body mass index (BMI) greater than 25
kg/m
2 and obesity as BMI greater than 30 kg/m
2 [1]
(Table 1). The obese state is increasingly more prevalent
in Western society and in some countries is the most
prevalent body composition [2,3].
Adipose tissue is principally deposited in two com-
partments - subcutaneously and centrally (Figure 1). It
is thought that centrally deposited, or visceral, fat is
more metabolically active than peripheral subcutaneous
fat [4-6]. Visceral adipose tissue is largely comprised of
omental adipose tissue but also includes other intra-
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adipose tissue secretes a number of adipokines and cyto-
kines leading to a proinflammatory, procoagulant and
insulin resistant state collectively known as the meta-
bolic syndrome [7]. The importance of adipose tissue
location in terms of dysmetabolism risk is evident as
central obesity is more strongly associated with
increased risk of insulin resistance, the metabolic syn-
drome and cardiovascular diseases than BMI alone [8].
For any given amount of total body fat, the subgroup of
individuals with excess visceral fat (versus subcutaneous
fat) is at higher risk of developing insulin resistance [9]
and the features of the metabolic syndrome [10].
Visceral fat remains more strongly associated with an
adverse metabolic risk profile even after accounting for
the contribution of other standard anthropometric
indices [11]. These systemic effects exerted by visceral
adiposity are putatively involved in cancer biology [12]
and are the focus of much research.
Measuring Visceral Adiposity
Commonly used BMI cut-off values to diagnose obesity
have high specificity, but low sensitivity to identify adip-
osity, as they fail to identify those with excess body fat
[13]. Waist circumference (WC) has been shown to be
an accurate predictor of visceral fat, either alone or in
combination with BMI [14]. WC directly reflects total
abdominal fat mass [15,16] and gender and ethnic speci-
fic cut-offs can be used as reliable proxy values to pre-
dict an increased risk of the metabolic disease However,
WC fails to quantify the visceral and subcutaneous fat
compartments individually and there are no clearly
defined cut-off values for an increase in cancer risk.
Computed tomography (CT) imaging is the gold stan-
dard for the measurement of adiposity, since this allows
for direct quantification of adipose tissue and can distin-
guish between visceral and superficial fat compartments
[17]. In terms of cardiovascular risk, peripheral fat accu-
mulation (as measured by leg subcutaneous fat deposi-
tion) may be protective [11]. Therefore, waist:hip ratio
(WHR) measurements may be more relevant in deter-
mining CVD risk than WC alone. Whether this is the
case for cancer risk is not yet known.
Gender influence on visceral adiposity
Gender influences fat distribution, with women having a
greater amount of peripherally located subcutaneous fat
and men having a greater amount of centrally located
visceral fat [8]. Men store about 20-30% of their total
body fat in the visceral compartment irrespective of
their obesity status [18]. Women do not accumulate sig-
nificant quantities of visceral fat until a moderate level
of obesity is reached and non-obese women have very
small amounts of visceral fat [19]. On average, men
have twice as much visceral fat as women and demon-
strate a high prevalence of the obesity-related metabolic
diseases and the metabolic syndrome [20,21].
The cause of this gender difference is uncertain but
may be related to the higher amount of hepatic free
fatty acid delivery derived from lipolysis from visceral
fat that has been observed in women compared to men
[22]. In addition, oestrogen may be a key regulator in
mediating differences in adipose tissue distribution
between men and women [8]. Pre-menopause, women
have higher levels of subcutaneous adiposity and there
is a lower incidence of obesity associated dysmetabolism.
However, after menopause, circulating levels of
Table 1 Body Mass Index as a predictor of risk to health,
WHO (2004)
Classification BMI(kg/m
2)
Underweight < 18.50
Normal Weight 18.50-24.99
Overweight/Pre-Obese 25.00-29.99
Obese Class I 30.00-34.99
Obese Class II 35.00-39.99
Obese Class III ≥ 40.00
BMI, body mass index
Adipose tissue composition: 
 
Figure 1 Hallmarks of cancer and potential role of visceral
obesity in tumorigenesis
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more “male-like” with increased amounts of visceral
adiposity and a subsequent increased risk of obesity-
related metabolic disorders [8].
Obesity and cancer: epidemiology evidence
Epidemiological studies provide convincing evidence of
an association between obesity and cancer development
at numerous sites: oesophagus (adenocarcinoma), pan-
creas, colorectum, breast (postmenopausal), endome-
trium and kidney [23]. The largest meta-analysis to date
includes 282,000 patients from prospective observational
studies with over 133 million person-years of follow-up
[24]. This shows that high body mass index is associated
with an increased incidence of many types of cancer.
The association is modest with risk estimates of 1.1 to
1.6 per 5 kg/m
2 incremental increase in BMI. This 5 kg/
m
2 increase in BMI corresponds to 15 kg weight gain in
m e na n d1 3k gi nw o m e nw i t ha na v e r a g eB M Io f2 3
kg/m
2. The associations between obesity and cancer are
sex and site specific but broadly consistent across geo-
graphic populations [24]. Emerging evidence suggests
that weight loss following bariatric surgery leads to a
reduction in cancer incidence [25]. The association also
fulfils many of Hill’s postulates [26] (plausible biological
mechanisms, consistent associations, sufficient latency
period, reversibility) indicating that the obesity is likely
to be causal.
Furthermore, a prospective study of 900,000 adults in
the United States reported that obesity could account
for 14% of all deaths from cancer in men and 20% in
women [27]. Those with a BMI greater than 40 kg/m
2
had a death rate 52% higher in men and 62% higher in
women when compared to those of normal weight. This
indicates that obesity may also affect outcomes following
cancer diagnosis and this finding is supported by other
studies which control for increased peri-operative mor-
tality rates amongst the obese [28-31].
There appears to a sex differential with respect to risk
of cancer development with men having a higher risk of
developing cancer at increased BMI than women
[24,32]. This may be due to the differing hormonal
milieu in females or it may reflect the fact that BMI
poorly reflects central adiposity in females. Since females
generally only deposit central adipose tissue once total
fat volumes are raised, overweight BMIs do not corre-
spond with visceral fat volume in females as they do in
males which may account for the differences in cancer
risk seen when BMI is used to determine obesity status.
In studies that use measures of visceral adiposity such
as WC or VFA, visceral adiposity is associated with
increased risk of cancer development [32-34]; is a stron-
ger predictor of cancer risk than BMI [32] and the can-
cer risk is similar in males and females [32,33]. Further,
larger studies using measures of visceral adiposity across
cancer sites are awaited in order to clarify whether there
is a clear differential effect of visceral versus subcuta-
neous obesity.
Visceral adiposity (and not subcutaneous adiposity) is
associated with development of features of the metabolic
syndrome (taken as a proxy measure of a dysmetabolic
profile in viscerally obese patients)[35]. Most of the com-
ponents of the syndrome, alone [36,37] or in combination
[38-40], have been individually link with cancer develop-
ment at various subsites. A prospective international
population-based study of 580,000 people (Me-Can
Study) is underway to identify whether the metabolic
syndrome is independently associated with cancer devel-
opment [41]. Initial findings suggest that a combination
of components of the metabolic syndrome is associated
with risk of colorectal cancer development (Men: RR:
1.25 (95% CI; 1.18-1.32; Women: RR 1.14 (95% CI; 1.02-
1.18)[42], endometrial cancer (RR 1.37, 1.28-1.46)[43],
bladder cancer in men (RR: 1.1, 1.01-1.18)[44] and pan-
creatic cancer in women (RR,1.58; 1.34-1.87)[45].
Mechanisms underlying obesity and
tumorigenesis
Long thought of as inert, adipose tissue, particularly
visceral fat [46], is an important metabolic tissue which
secretes factors systemically that alter the immunologi-
cal, metabolic and endocrine milieu and promote insulin
resistance [4]. The obese state may be thought of as a
pro-tumorigenic environment which can act to facilitate
tumour development by promotion of the acquisition of
some of the hallmarks properties that characterise can-
cerous lesions (Figure 1)[47,48].
Paracrine mechanisms
Adipose tissue may act in both a paracrine and systemic
manner. At a local level, adipose tissue is involved in a
number of mechanisms which may promote tumor
development (Figure 2). Obese mice have reduced levels
of oxygen within their epididymal adipose tissue [49].
The tumor microenvironment in solid tumors is often
characterised by low oxygen tensions and hypoxia
within the peri-tumoral fat may promote tumor-site
hypoxia. Hypoxia upregulates the hypoxic-inducible
Figure 2 Paracrine mechanisms linking adipose tissue and
cancer development
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over 60 target genes involved in angiogenesis, glycolysis,
cell proliferation and apoptosis, leading to cellular adap-
tation to low oxygen conditions [50]. Hypoxia has been
associated with metastasis and poor prognosis [51] and
also induces pro-angiogeneic and inflammatory cytokine
secretion [52-54].
Inflammatory cytokines produced in adipose tissue can
upregulate nuclear factor-B( N F B) which leads to an
increase in nitric oxide (NO), a substrate for reactive oxy-
gen species (ROS). Cytokines and ROS can contribute to
insulin resistance and the resultant excess circulating glu-
cose, free fatty acids and insulin can further induce inflam-
mation [55]. The key inflammatory pathways NFBa n d
STAT3 are activated by adipose tissue products leading to
transcription of genes which mediate proliferation, inva-
sion, angiogenesis, survival and metastasis [56].
The observation that epithelial tumor cell growth is
enhanced by injection into fat pads rather than subcuta-
neously [57] supports the hypothesis that chemokine
production within the adipose tissue provides conditions
which enhance tumor cell growth. A proteomic study of
mammary fat revealed the production of a wide variety
of proteins involved in diverse processes such as cell
communication, growth, immune response, apoptosis
and numerous signalling molecules including hormones,
cytokines and growth factors [58].
While fat which surrounds individual organs may act
in a paracrine manner to influence tumor development
or progression, this mechanism is less fully investigated
and most research efforts have concentrated on systemic
alterations in obesity and how these may influence can-
cer development and progression. Adipokine production
and inflammatory alterations in the obese state
described in detail hereafter may act to influence tumor-
igenesis in either a systemic or paracrine manner or a
combination of both.
Systemic mechanisms
Systemic alterations in obesity include chronic systemic
inflammation, increased adipokine production and an
altered immunological status (Figure 3). Additionally,
Figure 3 Systemic alterations in visceral adiposity which may contribute to a pro-tumorigenic microenvironment.
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Insulin resistance develops as a consequence of visceral
adiposity and there is a rise in insulin production, which
may be associated with activation of the insulin-like
growth factor (IGF) system. All of these changes which
occur in tandem with the development of obesity have
the ability to interact with each other. It is this altered
systemic milieu which is thought to fuel cancer develop-
ment and progression.
Chronic inflammation and adipokines
Excess adipose tissue results in elevated levels of pro-
inflammatory adipokines, resulting in an imbalance
between increased inflammatory stimuli and decreased
anti-inflammatory mechanism leading to persistent low-
grade inflammation [46,59,60]. The level of adipokine
production from adipose tissue is strongly influenced by
immune cell populations present in adipose tissue
[4,61-63]. Adipose tissue in obese people is infiltrated
with macrophages and the number of macrophages cor-
relates with the degree of adiposity [64]. Peripheral
monocytes are recruited by monocyte chemoattractant
protein (MCP)-1 and TNF-a, and can differentiate into
activated macrophages [65]. Pre-adipocytes also have the
ability to differentiate into macrophages [61]. The pro-
ducts of activated macrophages can impact on adipocyte
function and are postulated to be involved in altering
adipose tissue glucose handling and thus contribute to
insulin resistance [66,67]. Research has shown that co-
culture of adipocytes with macrophage-conditioned
media causes increased adipokine and inflammatory
cytokine production by adipocytes [68], further support-
ing this hypothesis.
Insulin can modulate adipokine production and inter-
acts with two of the most abundant adipokines: leptin
and adiponectin. Insulin is a positive regulator of leptin
and increases its gene expression to suppress appetite
[69]. Adiponectin acts as an insulin sensitising agent
[69]. In addition to modulation of insulin sensitivity,
these adipokines can directly affect tumor cells [70].
Adiponectin is anti-tumor: it increases apoptosis[71],
inhibits proliferation, inflammation and angiogenesis
[72] and can prevent the interaction of growth factors
with their receptors [73]. There is a consistent inverse
relationship with cancer incidence and circulating adipo-
nectin [74]. The pro-tumor effects of leptin are the
direct opposite of those of adiponectin [74], although
the epidemiological association between circulating
levels and cancer risk is less consistent [75]. Circulating
levels of leptin positively correlate and adiponectin levels
negatively correlate with all measures of obesity (BMI,
WC and visceral fat area)[76-78].
Thus altered adipokine production by adipose tissue,
and in particular inflammed visceral adipose tissue, may
influence the tumor microenvironment. Obese rat
models have increased inflammatory transcription factor
expression (TNFa and NFB) in their tumors [79].
Furthermore, there is emerging evidence that adipose
stromal cells may be a source of stromal cells in tumor
microenvironments. Early adipocyte precursor cells can
differentiate into stromal cells [80]. In animal models of
obesity, adipose stromal cells and adipose endothelial
cells from inflamed visceral adipose tissue migrate to
tumor sites [81]. Stromal cells in the tumor microenvir-
onment promote angiogenesis and support tumor pro-
gression [82]. There is also evidence that visceral
adiposity can influence a patient’s treatment outcome,
with a study demonstrating increased visceral fat area to
be an independent predictor of outcome after first-line
bevacizumab treatment in colorectal cancer [83]. This
finding indicates that angiogenic factors produced by
visceral fat may influence tumor progression and
response to chemotherapy and is mirrored in animal
models as adiponectin, which is reduced in visceral obe-
sity, inhibits tumor growth by reduced neovascularisa-
tion[72]. The mechanism(s) for this resistance may
uncover important information on how obesity influ-
ences the tumor microenvironment.
Sex hormones
Epidemiological studies haves u g g e s t e dad i f f e r e n c ei n
the influence of obesity on cancer development between
men and women [27]. While some studies are inconsis-
tent, the risk of colorectal cancer in post-menopausal
women does not seem to be related or only weakly asso-
ciated with obesity [84,85]. It has been hypothesised that
different distributions of adipose tissue between men
and women accounts for the difference [86]. Whether
this is mediated by affecting circulating sex hormone
levels is not fully understood. Adiposity is inversely
related to testosterone concentration in men but posi-
tively related in women [87]. Excess adipose tissue leads
to increased conversion of androgenic precursors to oes-
tradiol by increased aromatase activity [88]. In endome-
trial cancer, oestradiol increases cell proliferation via
inducing a local increase in IGF-1 [89].
Different influences of circulating oestrogen levels may
influence cancer development [90]. Chronic hyperinsuli-
naemia may promote tumorigenesis in oestrogen-sensi-
tive tissues as it reduces circulating sex-hormone
binding globulin and thus increases bioavailable oestro-
gen [27,91-93]. The association between obesity and
postmenopausal breast cancer risk is accounted for by
the increased serum oestradiol levels as obesity increases
[94] and since in females, most fat deposition occurs
peripherally, this fat area may be of more relevance to
endometrial and post-menopausal breast cancer risk.
Insulin resistance
L e v e l so fa d i p o s et i s s u ea f f e c tt h eb o d y ’s handling of
glucose [95]. Adipokines are thought to be involved in
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viously mentioned insulin can modulate adipokine activ-
ity. High concentration of cytokines produced by
adipose tissue, such as TNF- a,I L - 6 ,I L - 1 b,a n dl o w
concentrations of adiponectin, have deleterious effects
on glucose homeostasis leading to chronic hyperinsuli-
naemia and insulin resistance in Type 2 Diabetes Melli-
tus [98,99].
Insulin resistance is an adaptive response to raised cir-
culating free fatty acids (FFAs) and thus is related to the
extent of visceral adipose tissue deposits [100]. Raised
FFAs shift metabolism of liver, muscle and other tissues
towards lipid deposition and oxidation and away from
gluconeogenesis and glycolysis. Insulin secretion rises to
compensate for the decreased capacity to handle glu-
cose. Despite this there is a decreased expression of
insulin-receptor levels and reduced intracellular insulin
signalling in response to insulin receptor binding [101].
Subcutaneous adipose tissue takes up free fatty acids
and stores the excess calories more readily than visceral
adipose tissue [102]. Rates of lipolysis are higher in visc-
eral adipocytes than superificial [11], due to the anti-
lipolytic effect of insulin being increased in subcuta-
neous adipose tissue [46]. Therefore, the risk of develop-
ing insulin resistance is related to the size of visceral fat
deposits.
Several epidemiological studies have shown that insu-
lin resistance status, characterised by hyperinsulinaemia,
is associated with an increased risk for a number of
malignancies, including carcinomas of the breast, pros-
tate and colon[103-106]. Per 1 mmol/l increment in glu-
cose from data of the MeCan study cohort has revealed
an increase risk of incident cancer in men (RR 1.05,
1.01-1.1) and women (1.11, 1.05-1.16) and a further
increased RR for fatal cancer (Men: 1.15, 1.07-1.22;
Women: 1.21,1.11-1.33)[103].
Insulin and cancer
Insulin can act as a mitogen and has been associated
with several cancers[107]. The tumorigenic effects of
insulin could be directly mediated by insulin receptors
in the pre-neoplastic target cells, or might be due to
related changes in endogenous hormone metabolism,
secondary to hyperinsulinaemia [100]. Epidemiological
studies are hampered by the heterogeneity of diabetic
patients with respect to their degree of glycaemic con-
trol which will influence their circulating insulin levels
and hence making correlations with cancer development
difficult.
Epidemiological studies have shown that serum C-
peptide, as a proxy measure of insulin release, is asso-
ciated with increased risk of cancer of the colorectum,
post-menopausal breast, pancreas and endometrium
[108] and that type 2 diabetes is associated, independent
of obesity, with breast, pancreas, kidney, endometrial,
colorectal and bladder cancer [109]. Cohort studies have
demonstrated increase risk of colorectal cancer in those
with insulin resistance,[38,40,110] the metabolic syn-
drome [111] and type 2 diabetics [112]. The risk of can-
cer-related mortality is increased in those with high
insulin levels or insulin resistance and cancers of the
breast [113], prostate [114] and colorectum[115]. Color-
ectal cancer incidence is higher in Type 2 diabetics trea-
ted with insulin [116].
In vitro studies support epidemiological data in that
insulin increases the neoplastic proliferation of cell lines
at both physiological and pharmacological doses [117]
and the insulin receptor is commonly expressed in
human neoplasms. Under investigation at present is
whether there are differential effects downstream signal-
ling effects in normal or transformed epithelial cells
compared to insulin-responsive tissues (such as fat, liver
and muscle) with receptor activation resulting in cell
survival and proliferation rather than altered energy
metabolism [118]
Insulin-like growth factors, obesity and cancer
The interaction between insulin, body fat and the IGF
axis is less well understood. It has been proposed that
the IGF system mediates the effect of hyperinsulinaemia
and is more relevant to cancer development and pro-
gression than insulin (Figure 2). The insulin-like growth
factors are involved in enhancement of cell proliferation,
differentiation and apoptosis and have been implicated
in tumorigenesis [119,120]. Levels of IGF are influenced
by circulating insulin levels which alter the level of IGF
binding protein 1 and 2 (IGFBP1 & 2) increasing bioa-
vailability of IGF [121].Waist circumference and waist:
hip ratio are inversely associated with IGFBP1 levels in
healthy females[122]. The collective findings from a
number of studies show that IGFBP1 & 2 is inversely
associated with body fat and insulin levels and that
there does not appear to be a direct correlation between
total IGF1 levels and body fat or insulin [123]. Rather,
there is a non-linear relationship between BMI and total
IGF-1 levels (with the highest levels in those with a BMI
up to 27 kg/m
2[124]) However, the relationship between
measures of visceral adiposity and IGF-1 levels is
unclear. In addition, there is a debate as what constitu-
tes bioavailable IGF-1 (total or free fractions) and
whether IGFBPs and their relationship to total IGF-1
levels should be taken into account.
The IGF axis
The IGF axis is a multifunctional system with a variety
of molecular and biological effects. To date, 15 molecu-
lar functions and 29 biological processes have been
linked to the IGF-1R in the gene ontology database
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are ubiquitously expressed but at different levels in dif-
ferent tissues and with varying roles in each tissue. The
IGF axis can have auto-, para- and endocrine effects.
The main biological processes that the IGF axis is
involved with can be summarised as: control of normal
growth [118,125] (and perhaps lifespan [126]); mainte-
nance of tissue homeostasis [127] and a differentiated
phenotype [128]; alteration in the balance of prolifera-
tion and apoptosis [129]; angiogenesis, cell adhesion,
migration and wound healing [129].
IGF-1 and IGF-2 are bound by 6 high affinity binding
proteins (IGFBP1-6) and other low affinity binding pro-
teins (IGFBP-related proteins). IGFBP1-5 have higher
affinities for IGF-1, whereas IGFBP6 has a higher affinity
for IGF-2 [130]. IGFBPs stabilise and prolong the half-
life of IGFs and by binding IGFs prevent their binding
to receptors. IGFs are released from IGFBPs by dissocia-
tion or protease-mediated IGFBP cleavage [130]. Thus
IGFBPs alter the bioactivity of IGF and in some circum-
stances act to increase the bioactivity of IGF. This is
thought to occur by IGFBPs binding IGFs in proximity
to their receptor and acting to concentrate IGFs at
receptors and through the slow release of the growth
factors can influence the duration of signalling via the
receptor [130]. Another hypothesis is that IGFBP2 binds
an integrin-linked kinase to increase IGF bioactivity
[118]. The tumor suppressor p53, vitamin D, anti-oes-
trogens, retinoids and TGFb reduce the bioactivity of
IGFs by increasing secretion of IGFBPs [130]. IGFBPs
may also have independent effects on proliferation,
adhesion and motility. Certain IGFBPs modulate Wnt
signalling which is involved in differentiation and this
modulation is influenced by local concentrations of IGF
ligands [131]. Thus the IGF system is highly regulated
via a dynamic system of binding proteins which influ-
ence growth factor stability, receptor binding and dura-
tion of receptor activation.
IGF-1R is a transmembrane heterotetrameric protein
encoded by the IGF-1R gene located on chromosome
15q25-q26. IGF-1R is composed of two a and two b
subunits. Due to structural homology with the insulin
receptor it can heterodimerize with it. The IGF-1R
receptor binds (ranking from high to low affinity): IGF-
1, IGF-2 and insulin[132]. IGF-1R is a tyrosine kinase
receptor which initiates intracellular signalling upon
receptor activation by autophosphorylation and stimula-
tion of tyrosine kinase activity, leading to recruitment
and phosphorylation of the insulin-receptor substrate-1
(IRS-1). These receptor substrates activate two main sig-
nalling pathways: PI3K-AKT and RAS-Raf-MAPK which
have multiple effects on gene regulation and protein
expression, activation and translocation [129]. The avail-
ability, location and ratios of receptor substrates
influence cellular responses to receptor activation and
may also alter the balance of IGF signalling and insulin
signalling when heterodimers of IGF/insulinR are
bound. Several mechanisms of crosstalk which influence
IGF-1R receptor function have been describes including
heterodimers with EGFR[133] and SOCS interactions
influencing the Jak-Stat pathway[134].
IGF axis and cancer
Two of the hallmarks of cancer [47] are limitless repli-
cation and evasion from apoptosis (Figure 1). The IGF
axis is a central regulator of growth and survival. It has
been found that IGF-1R plays a role in the establish-
ment and maintenance of cellular transformation [135].
IGF-1R or its ligands are often over-expressed in human
tumors [136,137] and its action protects against apopto-
s i sa n df a v o u r si n v a s i o na n dmetastasis [119,120,129].
Activation of IGF-1R can promote cell migration and
the redistribution of E-cadherin and a-a n db- catenins
from adherens junctions into the cytoplasm [138]. IGF-1
also modulates the activities of integrin-coupled proteins
(FAK, p130, Cas and paxillin) through dephosphoryla-
tion [139].
The IGF-1R is commonly expressed by neoplastic cell
lines and human cancers and on circulating tumor cells
[136,137,140]. However, gene amplification is not com-
monly associated with protein overexpression or ligand-
independent activation [118]. The IGF-1R has been
found to be essential for oncogenic transformation in
some cellular systems. Mouse fibroblasts cannot be
transformed by the oncogenes: SV40 T antigen, papillo-
mavirus E5 and Ras overexpression if they lack the IGF-
1R [135]. Stable (constitutive) activation of IGF-1R is
insufficient to cause mammary epithelial cell transfor-
mation in mouse models [141].
Many cell lines are mitogenically responsive to physio-
logical concentrations of IGFs [132]. Increased prolifera-
tion in response to raised IGF levels may fuel the
development of early cancers. Using prostate cancer as a
model, there appears to be an increased likelihood of
progression to clinically detectable malignancy in
patients with higher IGF-1 levels such that baseline
IGF-1 level predicts progression to prostate cancer more
accurately than prostate-specific antigen in screened
populations [142,143]. In vivo animal models using nat-
ural occurring mutations associated with low IGF levels
[144,145] or genetic manipulations to influence ligand
levels [146,147], result in variability of neoplastic growth
related to IGF activity. Animal models have shown
decreased tumor growth after IGF1R inactivation and
with decreased circulating or tissue levels of IGF1
[121,148].
Studies of patients with acromegaly [149] or Laron
dwarfisim [150] have been used as proxies to identify
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They provide circumstantial evidence that increased
IGF-1 levels are associated with cancer. Other forms of
circumstantial evidence include the observation that
height and birth weight, which is related to the concen-
tration of IGF-1 in the umbilical cord, are related to the
risk of some cancers [151-153]. Mammographic breast
density, which is a strong risk factor for breast cancer is
related to the level of circulating IGF-1 genes [154,155]
and to polymorphisms in IGF-related genes [154,156].
Population based studies have provided evidence that
relate circulating ligand levels as well as polymorphic
variation of relevant genes to cancer risk and prognosis.
Prospective epidemiologic studies provide evidence of a
relationship between circulating IGF-1 and the risk of
developing prostate, breast, colorectal and other cancers
[142,143,157-161]. Individuals at the high end of the
normal range of serum IGF-1 have more than double
the risk of a subsequent cancer. Variability between stu-
dies, particularly regarding the potential reciprocal rela-
tionship between IGFBP3 and IGF-1 levels may be
accounted for by technical challenges in measuring IGF
and uncharacterised factors that modify IGF-1 levels
including age and diurnal variation. Studies of single
nucleotide polymorphisms in the IGF-1 axis genes indi-
cate a potential relationship between SNPs and circulat-
ing levels [154,162] but increased risk of cancer
development with IGF SNPs is unclear[163]. Studies
report polymorphic variants associated with colorectal
[164], oesophageal [165], ovarian [166] and non-small
cell lung cancer [167] but not with breast or prostate
cancer [168]. These studies require confirmation in
other populations.
IGF axis and obesity
Alterations in the IGF axis have been implicated in
malignancies that are also associated with obesity, sug-
gesting the IGF axis may play a mechanistic role in link-
ing obesity and cancer. There is a paucity of studies
examining the influence of obesity on IGF-1R in tumor
tissue. A study in breast cancer demonstrated that
increasing BMI was positively associated with increased
IGF-1R expression in both normal mammary gland tis-
sue and breast cancer tissue [169]. Furthermore research
has found that IGF-1R expression is significantly higher
in the colorectal neoplasms of individuals with meta-
b o l i cs y n d r o m et h a ni nt h el e sions of individuals with-
out the syndrome [170]. The findings of these studies
suggest that the molecular consequence of obesity is the
increased expression of IGF-1R in both normal and
malignant tissue.
As mentioned previously, elevated levels of free IGF-1
have been reported in obese individuals and are believed
to be a consequence of hyperinsulinaemia inhibiting
production of IGFBP-1 and -2[123,171]. The chronic sys-
temic inflammation associated with obesity is believed to
fuel tumor development and progression, and IGF-1 may
mediate obesity-associated inflammation via its effects on
immune cells, including macrophages. Studies have
shown IGF-1 can lead to macrophage migration and
invasion, and also increased macrophage production of
proinflammatory cytokines [172,173]. In addition, recent
research has supported a functional role for IGF-1 in
obesity associated inflammation and tumorigenesis. In a
murine model of obesity and chronic IGF-1 gene defi-
ciency, diet-induced obese mice demonstrated increased
local tumor growth and metastases compared to lean
controls, but this was not seen in IGF-1 gene deficient
mice. In addition, the expression of inflammatory cyto-
kines and cell adhesion molecules was upregulated in
obese compared to lean mice, but chronic IGF-1 defi-
ciency was associated with a reduction in these indicators
[174]. Hence it is possible that in obesity IGF-1 can affect
tumor development both directly, by stimulating tumor
growth and indirectly, by creating a microenvironment
that is permissive for tumor growth.
Summary and future directions
Obesity is likely to a causal factor for a number of com-
mon cancers, however, the mechanisms underpinning
this association are not fully understood. Current
hypotheses include the development of chronic inflam-
mation with increased adiposity, which alters immune,
sex steroid and adipokine function. In turn, alterations
in insulin sensitivity and the IGF axis occur. Any or all
of these systems act in concert to promote the develop-
ment and progression of cancer at a cellular level. How
these systemic conditions interact at the tumor site and
whether their influence is site-specific, is a complex
question. There has been little investigation of paracrine
models of adipose tissue function in the obese state.
Some of the systemic changes associated with obesity
are enhanced in the group of patients with visceral adip-
osity. Similar to the increased risk associated with cen-
tral obesity and development of cardiovascular and
metabolic disease, visceral fat may be more relevant to
cancer development. Studies which measure central obe-
sity as well as BMI may clarify whether total fat or visc-
eral fat distribution is most relevant.
Future research using accurate definitions of obesity
status are important in order to accurately determine
the risk associated with obesity and whether the risk is
specific to visceral fat.
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